Biblio

Author [ Title(Desc)] Type Year
Filters: First Letter Of Title is J  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
J
Yuan Y, Lu X, Chen X, Shao H, Huang S. Jagged1 contributes to the drug resistance of Jurkat cells in contact with human umbilical cord-derived mesenchymal stem cells. Oncol Lett. 2013;6(4):1000-1006.
Cahill EF, Tobin LM, Carty F, Mahon BP, English K. Jagged-1 is required for the expansion of CD4(+) CD25(+) FoxP3(+) regulatory T cells and tolerogenic dendritic cells by murine mesenchymal stromal cells. Stem Cell Res Ther. 2015;6(1):19.
Warsch W, Walz C, Sexl V. JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood. 2013.
Debeurme F, Lacout C, Moratal C, Bagley RG, Vainchenker W, Adrian F, Villeval J-L. JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice. J Cell Mol Med. 2015.
Wang X, Ye F, Tripodi J, Hu CSiang, Qiu J, Najfeld V, Novak J, Li Y, Rampal R, Hoffman R. JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood. 2014.
Langabeer SE, Haslam K. The JAK2 V617F mutation and thrombocytopenia. Hematol Oncol Stem Cell Ther. 2016.
Wu W, Fu J, Gu Y, Wei Y, Ma P, Wu J. JAK2/STAT3 regulates estrogen-related senescence of bone marrow stem cells. J Endocrinol. 2020.
Kong X, Gong Z, Zhang L, Sun X, Ou Z, Xu B, Huang J, Long D, He X, Lin X, et al. JAK2/STAT3 signaling mediates IL-6-inhibited neurogenesis of neural stem cells through DNA demethylation/methylation. Brain Behav Immun. 2019.
Vu T, Austin R, Kuhn CPaine, Bruedigam C, Song A, Guignes S, Jacquelin S, Ramshaw HS, Hill GR, Lopez AF, et al. Jak2V617F driven myeloproliferative neoplasm occurs independently of interleukin-3 receptor beta common signaling. Haematologica. 2015.
Zhang Y, Lin CHua Sarah, Kaushansky K, Zhan H. JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice through Thrombopoietin/MPL signaling. Stem Cells. 2018.
Li J, Kent DG, Godfrey AL, Manning H, Nangalia J, Aziz A, Chen E, Saeb-Parsy K, Fink J, Sneade R, et al. JAK2V617F-homozygosity drives a phenotypic switch between myeloproliferative neoplasms in a murine model, but is insufficient to sustain clonal expansion. Blood. 2014.
Sayoc-Becerra A, Krishnan M, Fan S, Jimenez J, Hernandez R, Gibson K, Preciado R, Butt G, McCole DF. The JAK-Inhibitor Tofacitinib Rescues Human Intestinal Epithelial Cells and Colonoids from Cytokine-Induced Barrier Dysfunction. Inflamm Bowel Dis. 2019.
Forbes LR, Vogel TP, Cooper MA, Castro-Wagner J, Schussler E, Weinacht KG, Plant AS, Su HC, Allenspach EJ, Slatter M, et al. Jakinibs for the Treatment of Immunodysregulation in Patients with Gain of Function STAT1 or STAT3 Mutations. J Allergy Clin Immunol. 2018.
Ojha R, Singh SK, Bhattacharyya S. JAK-mediated Autophagy Regulates Stemness and Cell Survival in Cisplatin Resistant Bladder Cancer Cells. Biochim Biophys Acta. 2016.
Staerk J, Constantinescu SN. The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective. JAKSTAT. 2012;1(3):184-190.
Rojas P, Sarmiento M. JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients. Acta Haematol. 2020:1-5.
Mohri T, Iwakura T, Nakayama H, Fujio Y. JAK-STAT signaling in cardiomyogenesis of cardiac stem cells. JAKSTAT. 2012;1(2):125-130.
Stine RR, Matunis EL. JAK-STAT Signaling in Stem Cells. Adv Exp Med Biol. 2013;786:247-67.
Bausek N. JAK-STAT signaling in stem cells and their niches in Drosophila. JAKSTAT. 2013;2(3):e25686.
W Y Lau W, Hannah R, Green AR, Göttgens B. The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients. Blood. 2015;125(10):1679-81.
Dolatabadi S, Jonasson E, Lindén M, Fereydouni B, Bäcksten K, Nilsson M, Martner A, Forootan A, Fagman H, Landberg G, et al. JAK-STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma. Int J Cancer. 2019.
Tang Y, Tian XCindy. JAK-STAT3 and somatic cell reprogramming. JAKSTAT. 2013;2(4):e24935.
Turaga SM, Silver DJ, Bayik D, Paouri E, Peng S, Lauko A, Alban TJ, Borjini N, Stanko S, Naik U, et al. JAM-A functions as a female microglial tumor suppressor in glioblastoma. Neuro Oncol. 2020.
Cyranoski D. Japan poised to allow 'reprogrammed' stem-cell therapy for damaged corneas. Nature. 2019.
Sawai T, Hatta T, Fujita M. Japan Significantly Relaxes Its Human-Animal Chimeric Embryo Research Regulations. Cell Stem Cell. 2019;24(4):513-514.

Pages